Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 319

Sort by

Sort Order Select

Journal Articles

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Alexander Röth, Wilma Barcellini, Shirley D'Sa, Yoshitaka Miyakawa, Catherine M Broome, Marc Michel, David J. Kuter, Bernd Jilma, Tor Henrik Anderson Tvedt, Stella Lin, Xiaoyu Jiang, Caroline Reuter, William Hobbs, Sigbjørn Berentsen

Blood (2019) 134 (Supplement_2): LBA-2.

https://doi.org/10.1182/blood-2019-132490

Published: 2019

Journal Articles

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Blood (2019) 134 (Supplement_1): 4434.

https://doi.org/10.1182/blood-2019-130584

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

Jeffrey Teoh, PhD, Timothy G. Johnstone, PhD, Brian Christin, BS, Rachel Yost, Neil A. Haig, Mary Mallaney, Aditya Radhakrishnan, Heidi H. Gillenwater, MD, Tina Albertson, MD, Paul Guptill, Lauren F. Brown, Christopher G. Ramsborg, Ronald J. Hause, PhD, Ryan P. Larson, PhD

Blood (2019) 134 (Supplement_1): 593.

https://doi.org/10.1182/blood-2019-127150

Published: 2019

Journal Articles

VISTA Is a Novel Regulator of Macrophage Biology

Parth Shah, MD, Mohamed Eltanbouly, BSc, Nicole Smits, Aurelien Sarde, Randolph Noelle, Rodwell Mabaera, MD PhD

Blood (2019) 134 (Supplement_1): 2320.

https://doi.org/10.1182/blood-2019-131310

Published: 2019

Journal Articles

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

Max Yano, Jennie Rachel Lance, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4302.

https://doi.org/10.1182/blood-2019-127620

Published: 2019

Journal Articles

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Jennie Rachel Lance, Max Yano, Xiaokui Mo, PhD MAS, Dean Anthony Lee, MD PhD, Natarajan Muthusamy, DVM,PhD, John C. Byrd, MD

Blood (2019) 134 (Supplement_1): 4303.

https://doi.org/10.1182/blood-2019-131034

Published: 2019

Journal Articles

Bio-Inspired Artificial Red Blood Cell: Design, Pre-Clinical Results and Novel Indications

Allan Doctor, MD

Blood (2019) 134 (Supplement_1): SCI-4.

https://doi.org/10.1182/blood-2019-121115

Published: 2019

Journal Articles

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Blood (2019) 134 (Supplement_1): 1393.

https://doi.org/10.1182/blood-2019-125257

Published: 2019

Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD

Blood (2019) 134 (Supplement_1): 1410.

https://doi.org/10.1182/blood-2019-128485

Published: 2019

Journal Articles

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Jacqueline Rhen, BSc MSc MD, Susan L Heatley, PhD MD, Barbara McClure, BSc (Hons) PhD, Laura N Eadie, BSc (Hons) PhD, Jimmy Breen, BSc (Hons) PhD, Caitlin Schutz Schutz, BSc (Hons), Toby N Trahair, MBBS FRACP PhD, Andrew H. Wei, PhD FRACP, FRCPA, MBBS, Luciano Dalla-Pozza, MBBS FRACP, Rosemary Sutton, BSc MSc PhD, Kenneth F Bradstock, BSc(MD, MBBS, PhD FRACP, FRCPA, Michael Philip Osborn, MB, BS, Deborah L. White, PhD FFSc (RCPA)

Blood (2019) 134 (Supplement_1): 3949.

https://doi.org/10.1182/blood-2019-127788

Published: 2019

Journal Articles

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

Jung Hyun Her, Dominik Pretscher, Sungyoo Cho, Yu-Kyeong Hwang, Timm Hoeres, Rainer Boxhammer, Stefan Steidl, Maria Patra, Juergen Schanzer, Jan Endell

Blood (2019) 134 (Supplement_1): 3801.

https://doi.org/10.1182/blood-2019-128511

Published: 2019

Journal Articles

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

Blood (2019) 134 (Supplement_1): 3720.

https://doi.org/10.1182/blood-2019-129276

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Karen W.L. Yee, MD, Gail J. Roboz, MD, Casey L. O'Connell, MD, Elizabeth A. Griffiths, MD, Raoul Tibes, MD PhD, Katherine J. Walsh, MD, Wendy Stock, MD, Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Elias Jabbour, MD, Todd L. Rosenblat, MD MS, Jean-Pierre Issa, MD, Xiang Yao Su, PhD, Mohammad Azab, MD, Hagop M. Kantarjian, MD

Blood (2019) 134 (Supplement_1): 3846.

https://doi.org/10.1182/blood-2019-129845

Published: 2019

Journal Articles

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Christine Rivat, Natalia Izotova, Rachel Richardson, MSc, Danilo Pellin, Rachael Hough, Robert Wynn, MD, Kim Champion, Andre Lopes, Sara Ghorashian, FRCPath, PhD, Martin Pule, Adrian J. Thrasher, MBBS, PhD FMedSci, Luca Biasco, PhD, Persis J Amrolia, FRCP, FRCPath, PhD

Blood (2019) 134 (Supplement_1): 52.

https://doi.org/10.1182/blood-2019-125916

Published: 2019

Journal Articles

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood (2019) 134 (Supplement_1): 4455.

https://doi.org/10.1182/blood-2019-127480

Published: 2019

Journal Articles

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Ahmad Faisal Karim, PhD, Pooja Vir, PhD, Devi Gunasekera, MBBS, Allen I. Stering, MD, Kenneth Lieuw, MD PhD, Kathleen P. Pratt, PhD

Blood (2019) 134 (Supplement_1): 2413.

https://doi.org/10.1182/blood-2019-124803

Published: 2019

Journal Articles

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Gretchen Johnston, Haley E. Ramsey, PhDMSc, Kristy Stengel, PhD, Shilpa Sampathi, PhD, Pankaj Acharya, PhD, Maria Arrate, MSc, Matthew C. Stubbs, PhD, Timothy Burn, PhD, Scott Hiebert, PhD, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 2509.

https://doi.org/10.1182/blood-2019-130458

Published: 2019

Journal Articles

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Dimitrios Papaioannou, MD, Deedra Nicolet, MS, Kellie J Archer, PhD, Allison Walker, Krzysztof Mrózek, MD PhD, Andrew J. Carroll, PhD, Jessica Kohlschmidt, PhD, Ann-Kathrin Eisfeld, MD, Marius Bill, MD PhD, Christopher J. Walker, PhD, Geoffrey L. Uy, MD, Bayard L Powell, MD, Jonathan E. Kolitz, MD, Richard Stone, MD, John C. Byrd, MD, Ramiro Garzon, MD, Clara D. Bloomfield, MD

Blood (2019) 134 (Supplement_1): 2694.

https://doi.org/10.1182/blood-2019-125727

Published: 2019

Journal Articles

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Jaewoong Lee, PhD, Gang Xiao, PhD, Kadriye Nehir Nehir Cosgun, PhD, Huimin Geng, PhD, Ning Ma, PhD, Lai N Chan, PhD, Kohei Kume, PhD, Matthew Nix, PhD, Zhengshan Chen, MD PhD, Chun-Wei David Chen, PhD, Jianjun Chen, PhD, Vishal Khairnar, PhD, Arun P. Wiita, MD PhD, Andrei Thomas-Tikhonenko, PhD, Michael Farzan, MD PhD, Michael S. Diamond, PhD, Jae U Jung, PhD, Nagarajan Vaidehi, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 2782.

https://doi.org/10.1182/blood-2019-127615

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

FT819: Translation of Off-the-Shelf TCR-Less Trac-1XX CAR-T Cells in Support of First-of-Kind Phase I Clinical Trial

Lisocabtagene Maraleucel (liso-cel) Manufacturing Process Control and Robustness across CD19+ Hematological Malignancies

VISTA Is a Novel Regulator of Macrophage Biology

IL-21-Expanded Natural Killer Cells As Autologous Cell Therapy for CLL

IL-21-Expanded NK Cells As Autologous Cell Therapy for CLL

Bio-Inspired Artificial Red Blood Cell: Design, Pre-Clinical Results and Novel Indications

Molecular MRD Monitoring Is Feasible in the Majority of Children with AML and Is Highly Predictive of Outcome: Results from the International MyeChild01 Study

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

High Risk Genomic Alterations Identified at the Time of Diagnosis Are Strongly Associated with MRD and Subsequent Poor Outcomes in AYA ALL Patients Treated on a Pediatric Inspired Chemotherapy Regimen

Functional Characterization of Gamma Delta T Cells and Allogeneic Activated NK Cells As Effector Cells for Tafasitamab (MOR208)

High Burden of Clonal Hematopoiesis in First Responders Exposed to the World Trade Center Disaster

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration to Maximize Response and Survival Benefit. Survival Benefit Not Restricted to Patients with Objective Response

Clonal Dynamics of Early Responder and Long-Term Surviving CAR-T Cells in Humans

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Elispots and Ex Vivo Expansion of FVIII-Specific T-Cell Clones Confirm Specificity of CD4 + T-Cell Responses to Self-FVIII in Healthy Non-Hemophilic Blood Donors

Nascent Transcript and Single Cell Rnaseq Analysis Defines the Mechanism of Action of the LSD1 Inhibitor INCB059872 in Myeloid Leukemia

Next-Generation RNA Sequencing-Based Analysis Identifies a Novel Set of Prognostic Micrornas (miRs) in Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Ifitm3 Is Essential for PI(3,4,5)P3-Dependent B-Cell Activation and Leukemogenesis

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only